Argobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein Degradation
This press release features multimedia. View the full release here:
Enodia Therapeutics stems from pioneering research at the Institut Pasteur, with the discovery of the mechanism of action of Mycolactone, a natural Sec61 inhibitor responsible for Buruli Ulcers. 'Our infectious diseases research revealed a new way to target disease-causing proteins. This breakthrough highlights how fundamental research can help uncover entirely new therapeutic opportunities,' said Pr. Caroline Demangel, co-founder of Enodia Therapeutics and Head of the Immunobiology and Therapy Unit at the Institut Pasteur.
Rooted in groundbreaking research at the Institut Pasteur and supported by Argobio, Enodia Therapeutics received Pfizer x BioLabs' prestigious Golden Ticket Award. 'This recognition supports our newest small molecule Targeted Protein Degrader (TPD) developed by the combined teams of Argobio and the Institut Pasteur. We are grateful for Pfizer's support and proud to be part of the vibrant BioLabs life sciences ecosystem in Paris Hotel Dieu, where collaboration and innovation are driving significant advancements in healthcare,' Yves Ribeill remarked.
'Pfizer is committed to supporting innovative biotech startups that have the potential to redefine patient care. We are excited to see how Enodia Therapeutics will harness its technology for novel treatment approaches,' said Dr. Luca Mollo, Vice-President and Medical Director at Pfizer in France.
Enodia Therapeutics was incubated by Argobio, a premier French biotech studio company dedicated to fostering innovative science and accelerating its transition into a fully-fledged biotech company. The scientific project behind Enodia Therapeutics was supported by the Institut Pasteur's Innovation Accelerator. The aim of this program is to accelerate the market launch of innovative products resulting from laboratory discoveries. With the creation of its first spin-off company in 1997, the Institut Pasteur has been a pioneer in the creation of spin-off companies based on its research. To date the Institut Pasteur has been involved in the development of 38 spin-off companies.
About Enodia Therapeutics
Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell. Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source. Emerging from the Institut Pasteur and nurtured by Argobio, Enodia is built on breakthrough science with a singular mission: unveiling the translocon to unlock innovative therapies.
For additional information visit: https://home.enodiatx.com/
About Argobio
Argobio is a French biotech start-up studio committed to transforming cutting-edge innovations into groundbreaking biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.
For additional information visit https://www.argobiostudio.com/en/
About Institut Pasteur
The Institut Pasteur, a non-profit foundation with recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research. In the pursuit of its mission to tackle diseases in France and throughout the world, the Institut Pasteur operates in four main areas: research, public health, training, and development of research applications. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology, with research focusing on the biology of living systems. Among its areas of investigation are emerging infectious diseases, antimicrobial resistance, certain cancers, neurodegenerative diseases, and brain connectivity disorders. The Institut Pasteur's outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging, computational biology and artificial intelligence. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS.
The Institut Pasteur is part of the Pasteur Network a worldwide network of more than 30 members on five continents, united by Pasteurian values, that contribute to global health.
Since July 1, 2021, the Institut Pasteur is a research partner organization of Université Paris Cité.
CONTACT: For media inquiries, please contact:
Enodia Therapeutics - Argobio:
Morgane Schwenzer [email protected] de presse de l'Institut Pasteur :
Aurélie Perthuison
Anne Burlet-Parendel
SOURCE: Enodia Therapeutics
Copyright Business Wire 2025.
PUB: 02/26/2025 07:00 AM/DISC: 02/26/2025 07:03 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Newly promoted Ligue 1 side Paris FC signs striker Geubbels from St. Gallen
PARIS (AP) — Newly promoted Ligue 1 side Paris FC signed striker Willem Geubbels from Swiss team St. Gallen on a five-year contract on Sunday. Paris FC announced the signing with a video posted on X. No transfer fee was given but French sports daily L'Équipe said Geubbels cost 9 million euros ($10.5 million) with a further 2.5 million euros in eventual bonuses. The 24-year-old Geubbels came through Lyon's famed youth academy but hardly played for the club before joining Monaco. He scored one league goal there and two for Nantes before joining St. Gallen in 2023, where he scored 14 league goals last season. Paris FC has large funds at its disposal since its takeover by France's richest family, the Arnaults of luxury empire LVMH. The energy drink giant Red Bull acquired a minority stake. For the first time in 35 years two Paris-based soccer clubs are in Ligue 1. Furthermore, Paris FC has changed its home stadium since being promoted and will play at Stade Jean-Bouin, which is literally across the street from defending champion Paris Saint-Germain's Parc des Princes stadium. ___
New York Post
2 hours ago
- New York Post
Offbeat NYC graffiti tour survives despite predicted drop in foreign tourism thanks to visitors from this country: ‘They're obsessed with street art'
These tourists see the writing on the wall. French art lovers are flocking to industrial Brooklyn in droves for quirky walking tours of warehouses sprayed with graffiti and street art. Advertisement The niche fascination is still going strong despite a major industry group projecting a nearly 20% drop in overall foreign tourism to the Big Apple this year. 5 Audrey Connolly of Graff Tours leads a tour of street art and graffiti in Bushwick, Brooklyn. Stephen Yang 'There are so many people in France that are obsessed with graffiti and street art: It's been a huge part of our business for years,' Bushwick-based Graff Tours tour guide Audrey 'Byte' Connolly told The Post. Advertisement Connolly, who has led walking tours of the hipster neighborhood's urban art for nearly a decade, attributing trailblazing cultural similarities in New York and Paris for the grand amour. As tour guides across the city report an absence of usual visitors from Canada, Australia, Germany and other nations — possibly over political boycotts and tariff-related economic fears — French tourists are largely unbothered, Connolly said. 'They're obsessed with street art — hopefully, they keep coming.' 5 Connolly leads a group of tourists — two French families and one group from Kansas City, Missouri — on a tour through industrial Bushwick. Stephen Yang Advertisement Germans and Israelis — who also represent large swaths of Graff Tour patrons — have not booked nearly as much this year, and school groups from Canada and China have also dwindled, Connolly said. Antoine Jacquet, a 23-year-old Graff Tours customer from Dijon, France, said its been more difficult to clear immigration hurdles under the Trump administration. But he was able to make the overseas trip himself, and even predicted foreign tourism will 'probably pick up with the new mayor Zohran [Mamdani],' referring to the Democratic mayoral nominee, a socialist, because 'his policies are more based out of Europe than to America.' New York City Tourism + Conventions, the city's tourism authority, recently said that some 2 million fewer visitors from other countries are expected to make the trip to the Big Apple in 2025, a loss of roughly $4 billion in foreign tourism dollars. Advertisement August is typically one of the busiest months for tours, Connolly said, but during weeks this year when she would've typically been working for seven days straight, she's spent entire days off without a booking. 'Tourism has big-down market effects: it affects hotels, it affects small businesses, it affects [the] local economy,' said Graff Tours president Gabe Schoenberg. The impact has been felt in trendy Bushwick, from thrift shops to restaurants that cater to Euro families in the hipster shopping district, added Schoenberg. 5 Antoine Jacquet, 23, of Dijon, France, expects that tourism to the US will tourism will 'probably pick up with the new mayor Zohran [Mamdani].' Stephen Yang As French tourism to the biz remains strong, Schoenberg still reports a roughly 10% drop in overall foreign visitors since last year — and is now trying too woo domestic tourists and locals with targeted social media ads. 'We did better this year with domestic tourism than years past,' he said. But 'a lot of domestic tourists don't see [graffiti] as art,' Connolly said. 'They're being told to fear New York and everything about it.' Schoenberg also attributed the reluctance of foreign tourists to visit New York City to 'backlash' over President Trump and his policies, as well rising transportation and food costs and fears over tariff-related price increases. Advertisement 'Even for a New Yorker, prices are going up and prices are going up exponentially,' he said. 'But locally, either exemptions for tourism or some type of incentive for tourism could also help.' 5 While French tourism remains steady, Graff Tours has still seen a roughly 10% drop in overall foreign visitors since last year — and is now trying too woo domestic tourists and locals. Stephen Yang 5 Graffiti writer The Ghostface Mims teaches a workshop at Graff Tours. Stephen Yang Advertisement The president of the tour company — which has a Los Angeles outpost as well — attributed diversity in its offerings as its key to staying afloat in uncertain times. Aside from industrial walking tours, Graff Tours' Bushwick site also offers spray painting classes and has hosted corporate events for the likes of Meta, L'Oréal and even hosted an influencer-filled launch party for Samsung this summer. 'The class revenue is significant compared to the tour revenue,' Schoenberg said. 'If I was relying on tours in general, I don't think I would still be in business.'
Business Insider
12 hours ago
- Business Insider
Why LVMH Stock (MC) Is Catching Wall Street's Attention
French luxury products company LVMH Moët Hennessy Louis Vuitton, or LVMH (FR:MC) (LVMUY), is drawing strong support from Wall Street as several analysts maintain their Buy ratings. The recent wave of bullish ratings came despite the company reporting a challenging Q2 for 2025. Year-to-date, MC stock has declined more than 25%, reflecting broader market pressures on the luxury sector. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. LVMH is a European fashion house known for its iconic luxury brands like Louis Vuitton, Sephora, Fendi, Bulgari, and more. The company is primarily listed on the Euronext Paris exchange but also trades over-the-counter (OTC) in the U.S. LVMH Q2 2025 Results Overview In Q2, LVMH's core fashion and leather goods segment saw a sharp drop in sales, falling 9% year-over-year. The decline was larger than analyst expectations and marked the steepest drop among all of LVMH's business segments. This reflected continued weak demand for luxury products amid rising prices and economic uncertainty. Overall, LVMH's net profit dropped 22% year-over-year in the first half, while operating profit fell 15%. Looking ahead, the company warned that a full recovery will take time as it faces an industry-wide slowdown, with softer demand from Chinese shoppers and ongoing uncertainty among U.S. consumers. Wall Street Analysts Stay Bullish Despite the lackluster results, analysts have maintained their buy ratings on MC stock. Four-star-rated analyst Luca Solca at Bernstein reiterated his Buy rating on MC stock at a price target of €600, implying more than a 30% growth rate. Sola stated that the recent results showed effective cost control despite weak demand. He added that focus will now shift to how the company tackles its challenges and the potential impact on its business in the second half of the year. Likewise, RBC Capital's analyst Piral Dadhania maintained his Buy rating. He noted that while LVMH's recent underperformance presents a 'fairly attractive' risk/reward, it is supported by an expected near-term boost in Fashion & Leather Goods from easier comparisons. Is LVMH Stock a Good Buy? Overall, MC stock has received a Moderate Buy rating on TipRanks, backed by a total of 19 recommendations from analysts. It includes 10 Buys and nine Holds assigned in the last three months. The LVMH share price target is €565.14, which is 20% higher than the current trading level.
